KALA

KALA BIO, Inc. (KALA) | Rumor.io

KALA BIO

KALA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,984

Bullish sentiment (50-day avg)86%

Price to earnings ratio11.4

Market capitalization8.7M

Earnings per share-9.39

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-27M

Social

What share of all stock conversation is about KALA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% new	0% new	0% +0	0% +0

Sep 30

Kala Pharmaceuticals, Inc. ($KALA) may experience a potential run tomorrow, according to one post.
There is a bullish sentiment towards $KALA, with multiple posts expressing enthusiasm and predicting future price increases.
One post suggests keeping an eye on the stock if it holds above $0.72.

Generated by AI

Sentiment

Of the messages about KALA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.15%	93.15%	88.31% +88.31	74.07% -8.16
Bearish	6.85%	6.85%	11.69% -88.31	25.93% +8.16

Bullish· Sep 29

The asset's price has been dropping, but the author believes it will rise again, citing past performance as a reason for optimism.
The asset's chart has transitioned from background noise to the main focus, suggesting a shift in market attention and potential for increased price action.
The author expects the asset to break through key technical levels, such as the 10-day moving average, and potentially reach new highs.

Bearish· Apr 15

$KALA's delayed financial report and lack of timely communication may be a cause for concern.
The stock's price action may be influenced by its scheduled earnings release, with potential for volatility around the announcement.
Investors are considering cutting losses or selling their shares if the stock price drops further, citing disappointment with the company's performance.

Generated by AI

Topics

Of the messages about KALA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	42.86%	93.28%	94.2%	20.99%
Technical Analysis	57.14%	6.72%	5.8%	18.2%
Analysts	0%	0%	0%	27.7%
Controversies	0%	0%	0%	0.93%
Earnings	0%	0%	0%	0.04%
Macro	0%	0%	0%	32.14%

Analysts· Aug 14

Wedbush initiates coverage of Kala Pharmaceuticals ($KALA) with an outperform rating and a $46 price target, citing blockbuster market potential for dry eye disease flares.
Multiple analysts, including Wedbush, JPMorgan, and Wells Fargo, initiate coverage of Kala Pharmaceuticals ($KALA) with buy or overweight ratings, with price targets ranging from $24 to $46.
Kala Pharmaceuticals ($KALA) is identified as a differentiated opportunity in the growing eye disease market, with two promising programs, according to analysts at Wells Fargo and Wedbush.

Announcements· Mar 12

Kala Pharmaceuticals, Inc. ($KALA) is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market.
Kala's Researgency.ai platform is an agentic AI platform under development with Kala Bio, intended to bring autonomous research loops to biotechnology R&D planning, enabling agents to autonomously plan, simulate, and optimize research scenarios around the Researgency lock.
Kala's AI agents target three massive pain points in biotech and pharma companies: repetitive workflows that AI can run on autopilot, mountains of paperwork where one mistake can delay a drug by months, and costly delays where AI compresses work from weeks to days, or even hours.

Technical Analysis· Mar 11

$KALA has the potential to reverse back higher and gap up at open tomorrow morning if it closes above $0.35 and then runs green above $0.40.
The stock is showing signs of strong buying pressure, with buyers pushing it higher and momentum traders potentially trying another push toward $0.45-$0.50 if it can reclaim the key level around $0.40 with strong volume.
$KALA has formed a wide bottomed U shape on its technicals, which is considered a bullish sign, and is due for another run if this strength holds, with buyers continuing to defend pullbacks and the trend still intact.

Generated by AI

Community

Of the messages about KALA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	27.42%	17.81%	22.6%	10.15%
Newcomers	72.58%	82.19%	77.4%	89.85%

Regulars· Sep 29

$KALA has seen a significant increase in trading volume and price, up 21% since it was flagged, with a relative volume of 1.6x and a float rotation picking up at $0.65, with an RSI already extended at 89 but the MACD still showing a strong bull trend.
The regulars are focused on the potential for $KALA to break through the 21k wall at $0.51 and continue its upward trend, with one post stating that if it can drop from $20 to $0.5, it will go up to $10 again with the right outcomes.
$KALA's chart has moved from background noise to center stage, with a non-binding LOI signed to acquire a nationwide telehealth platform with approximately $48 million in sales since inception, which could be a catalyst for the stock's price to increase.

Newcomers· Sep 29

Newcomers are optimistic about Kala Pharmaceuticals, Inc. with some calling it "fun" and a "boom".
Several users believe Kala Pharmaceuticals, Inc. will reach $1 or higher, with one user predicting a 150% increase by the end of tomorrow.
There is a mention of a promissory note involving a $7,000,000 USD loan made to Minglemint Solutions LLC, which may be a concern for investors.

Generated by AI

News

KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Kala Bio (NASDAQ:KALA)

KALA Bio shares surge after hours after signing an LOI to acquire a nationwide telehealth platform.

6h agoBenzinga

Kala Bio signs letter of intent to acquire telehealth firm

23h agoInvesting.com

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual WellnessKey HighlightsTarget generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positiveProposed purchase price of approximately $15 million, payable in cash and.

23h agoYahoo Finance

Kala Bio signs letter of intent to expand genetic testing deal

5d agoInvesting.com

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitionsNEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq: KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions. Ms. Truong has spent roughly two decades in heal

12d agoYahoo Finance

Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing

19d agoInvesting.com

Also Discussed

Investors talking about KALA also mention

#	Name	Attention
1	AMAM - Ambrx Biopharma Inc.	——
2	GTHX - G1 Therapeutics, Inc.	——
3	TG Therapeutics Inc.TGTX	0.01%+0
4	Vaxcyte Inc.PCVX	0%0
5	Jasper Therapeutics, Inc.JSPR	0%0
6	Palisade Bio Inc.PALI	0%new
7	CytomX Therapeutics, Inc.CTMX	0%0
8	Cosmos Health Inc.COSM	0.02%+0.01
9	Minerva Surgical Inc.UTRS	0%0
10	IGMS - IGM Biosciences, Inc.	——

KALA BIO, Inc.

Healthcare
Biotechnology

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases of the eye. KALA BIO’s current work centers on biologics-based investigational treatments built on its proprietary mesenchymal stem cell secretome platform, with KPI-012 as its lead product candidate for persistent corneal epithelial defects and other corneal disorders. The company also evaluates the platform for broader ophthalmic applications, including limbal stem cell deficiency and retinal degenerative diseases. KALA BIO serves the biotechnology and pharmaceutical research space through its development pipeline and commercialization efforts, with an emphasis on unmet medical needs in eye health. Headquartered in Arlington, Massachusetts, KALA BIO operates as a specialized participant in the ophthalmology and biotechnology markets.

Website

Location

1167 Massachusetts Avenue

Arlington, MA, 02476

United States

Social

What share of all stock conversation is about KALA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% new	0% new	0% +0	0% +0

Sep 30

Kala Pharmaceuticals, Inc. ($KALA) may experience a potential run tomorrow, according to one post.
There is a bullish sentiment towards $KALA, with multiple posts expressing enthusiasm and predicting future price increases.
One post suggests keeping an eye on the stock if it holds above $0.72.

Generated by AI

Sentiment

Of the messages about KALA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.15%	93.15%	88.31% +88.31	74.07% -8.16
Bearish	6.85%	6.85%	11.69% -88.31	25.93% +8.16

Bullish· Sep 29

The asset's price has been dropping, but the author believes it will rise again, citing past performance as a reason for optimism.
The asset's chart has transitioned from background noise to the main focus, suggesting a shift in market attention and potential for increased price action.
The author expects the asset to break through key technical levels, such as the 10-day moving average, and potentially reach new highs.

Bearish· Apr 15

$KALA's delayed financial report and lack of timely communication may be a cause for concern.
The stock's price action may be influenced by its scheduled earnings release, with potential for volatility around the announcement.
Investors are considering cutting losses or selling their shares if the stock price drops further, citing disappointment with the company's performance.

Generated by AI

Topics

Of the messages about KALA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	42.86%	93.28%	94.2%	20.99%
Technical Analysis	57.14%	6.72%	5.8%	18.2%
Analysts	0%	0%	0%	27.7%
Controversies	0%	0%	0%	0.93%
Earnings	0%	0%	0%	0.04%
Macro	0%	0%	0%	32.14%

Analysts· Aug 14

Wedbush initiates coverage of Kala Pharmaceuticals ($KALA) with an outperform rating and a $46 price target, citing blockbuster market potential for dry eye disease flares.
Multiple analysts, including Wedbush, JPMorgan, and Wells Fargo, initiate coverage of Kala Pharmaceuticals ($KALA) with buy or overweight ratings, with price targets ranging from $24 to $46.
Kala Pharmaceuticals ($KALA) is identified as a differentiated opportunity in the growing eye disease market, with two promising programs, according to analysts at Wells Fargo and Wedbush.

Announcements· Mar 12

Kala Pharmaceuticals, Inc. ($KALA) is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market.
Kala's Researgency.ai platform is an agentic AI platform under development with Kala Bio, intended to bring autonomous research loops to biotechnology R&D planning, enabling agents to autonomously plan, simulate, and optimize research scenarios around the Researgency lock.
Kala's AI agents target three massive pain points in biotech and pharma companies: repetitive workflows that AI can run on autopilot, mountains of paperwork where one mistake can delay a drug by months, and costly delays where AI compresses work from weeks to days, or even hours.

Technical Analysis· Mar 11

$KALA has the potential to reverse back higher and gap up at open tomorrow morning if it closes above $0.35 and then runs green above $0.40.
The stock is showing signs of strong buying pressure, with buyers pushing it higher and momentum traders potentially trying another push toward $0.45-$0.50 if it can reclaim the key level around $0.40 with strong volume.
$KALA has formed a wide bottomed U shape on its technicals, which is considered a bullish sign, and is due for another run if this strength holds, with buyers continuing to defend pullbacks and the trend still intact.

Generated by AI

Community

Of the messages about KALA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	27.42%	17.81%	22.6%	10.15%
Newcomers	72.58%	82.19%	77.4%	89.85%

Regulars· Sep 29

$KALA has seen a significant increase in trading volume and price, up 21% since it was flagged, with a relative volume of 1.6x and a float rotation picking up at $0.65, with an RSI already extended at 89 but the MACD still showing a strong bull trend.
The regulars are focused on the potential for $KALA to break through the 21k wall at $0.51 and continue its upward trend, with one post stating that if it can drop from $20 to $0.5, it will go up to $10 again with the right outcomes.
$KALA's chart has moved from background noise to center stage, with a non-binding LOI signed to acquire a nationwide telehealth platform with approximately $48 million in sales since inception, which could be a catalyst for the stock's price to increase.

Newcomers· Sep 29

Newcomers are optimistic about Kala Pharmaceuticals, Inc. with some calling it "fun" and a "boom".
Several users believe Kala Pharmaceuticals, Inc. will reach $1 or higher, with one user predicting a 150% increase by the end of tomorrow.
There is a mention of a promissory note involving a $7,000,000 USD loan made to Minglemint Solutions LLC, which may be a concern for investors.

Generated by AI

KALA BIO

Social

Sep 30

Bullish· Sep 29

Bearish· Apr 15

Analysts· Aug 14

Announcements· Mar 12

Technical Analysis· Mar 11

Regulars· Sep 29

Newcomers· Sep 29

KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Kala Bio (NASDAQ:KALA)

Kala Bio signs letter of intent to acquire telehealth firm

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Kala Bio signs letter of intent to expand genetic testing deal

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing

Also Discussed

KALA BIO, Inc.

Company Information

Location

KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Kala Bio (NASDAQ:KALA)

Kala Bio signs letter of intent to acquire telehealth firm

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Kala Bio signs letter of intent to expand genetic testing deal

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing

Also Discussed

Social

Sep 30

Bullish· Sep 29

Bearish· Apr 15

Analysts· Aug 14

Announcements· Mar 12

Technical Analysis· Mar 11

Regulars· Sep 29

Newcomers· Sep 29